Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS)

Janus Henderson Group PLC cut its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 98.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,890 shares of the biotechnology company's stock after selling 998,117 shares during the quarter. Janus Henderson Group PLC's holdings in Merus were worth $944,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. HighTower Advisors LLC acquired a new stake in shares of Merus in the third quarter worth $358,000. Holocene Advisors LP grew its position in Merus by 4.1% during the third quarter. Holocene Advisors LP now owns 1,637,988 shares of the biotechnology company's stock worth $81,834,000 after buying an additional 64,122 shares in the last quarter. Verition Fund Management LLC grew its position in Merus by 16.6% during the third quarter. Verition Fund Management LLC now owns 42,746 shares of the biotechnology company's stock worth $2,136,000 after buying an additional 6,071 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Merus by 17.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company's stock valued at $4,207,000 after purchasing an additional 12,212 shares in the last quarter. Finally, Ally Bridge Group NY LLC boosted its holdings in Merus by 19.1% during the third quarter. Ally Bridge Group NY LLC now owns 208,244 shares of the biotechnology company's stock valued at $10,404,000 after purchasing an additional 33,400 shares in the last quarter. 96.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 9th. The Goldman Sachs Group assumed coverage on shares of Merus in a research report on Thursday, November 21st. They set a "buy" rating and a $73.00 target price for the company. Guggenheim reissued a "buy" rating and issued a $109.00 price target (down previously from $111.00) on shares of Merus in a report on Tuesday, December 3rd. Citigroup upped their target price on shares of Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Merus has an average rating of "Buy" and an average target price of $85.64.

Merus Price Performance

Merus stock traded up $1.38 during trading hours on Friday, hitting $42.83. The company had a trading volume of 416,827 shares, compared to its average volume of 681,367. The firm has a market cap of $2.93 billion, a PE ratio of -10.84 and a beta of 1.07. Merus has a one year low of $24.07 and a one year high of $61.61. The firm has a 50-day moving average of $48.97 and a 200 day moving average of $51.52.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.05). The business had revenue of $11.77 million during the quarter, compared to analyst estimates of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, research analysts expect that Merus will post -3.89 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.